unlocking Impossible

Solu Therapeutics is pioneering a new therapeutic modality to redefine what is possible and transform patient lives.

Our Platform

Our Platform

A powerful new type of antibody therapeutic

that unlocks cell surface targets

By linking potent and selective small molecules to effector antibodies in a unique way, we can target cell surface proteins that are not addressable using other therapeutic modalities

  • Using best-in-class small molecule binders, we can access deep binding pockets in receptors such as G protein-coupled receptors (GPCRs) and ion channels.  
  • We engineer the binders into bifunctional small molecules.   One arm engages the extracellular target while the other arm utilizes our proprietary platform linker technology to connect with one of our proprietary antibodies.
  • Our innovative linker technology allows us to create an entirely new class of drugs where bifunctional small molecules adopt the pharmacokinetic properties and functions of our antibodies.
  • This unique ability to combine our bifunctional small molecules and antibodies allows us to develop new medicines that were previously impossible to create.
Cytac
Bifunctional small molecule and linker
Drug Target
High-value cell surface target
Antibody
Proprietary fully humanized effector antibody

Unlock Targets

Access high value drug discovery targets that cannot be accessed using traditional therapeutic antibodies

Rapid Drug Development

Covalently attaching proprietary linkers to readily available clinical quality small molecules makes it possible for Solu to advance from concept to development candidate in about one year

Enhanced Specificity and Efficacy

The very low small molecule doses required in the Solu platform decrease safety risks, and the deep binding pockets for small molecules on drug targets enhance the efficacy of effector antibodies

CyTAC™

Cytotoxicity Targeting Chimera

Our proprietary CyTAC molecules link cell surface targets that mark pathogenic cells to proprietary platform antibodies that induce the killing of these cells

TicTAC™

Therapeutic Index Control Targeting Chimera

Our proprietary TicTAC molecules drive the tight association of potent and selective small molecule agonists or antagonists with an Fc-modified antibody, leading to the small molecule assuming the pharmacokinetic characteristics of the antibody. This can provide multiple advantages resulting in a superior profile for the therapeutic.

Pipeline

Our opportunity to target multiple areas of unmet need

Oncology

Discovery
Preclinical
IND-enabling
Ph1
Ph2

STX-0712

CCR2-CyTAC
Monocyte Depletor CMML
IND-Enabling

STX-0301

Novel Bispecific CyTAC
Prostate Cancer
Preclinical

Immunology & Inflammation

Discovery
Preclinical
IND-enabling
Ph1
Ph2

STX-0812

CCR2-CyTAC
Monocyte Depletor Inflammatory Disease
Preclinical

STX-0640

Novel Targeting CyTAC
Mast Cell Depletor Inflammatory Disease
Preclinical

Pain

Discovery
Preclinical
IND-enabling
Ph1
Ph2

Na ion channel TicTACs

Pain
Preclinical

Collaborate With Us

Submit ideas or contact us for collaboration opportunities

Our proprietary platform and approach present multiple opportunities for collaboration or partnership around existing programs or the potential to use our platform to support development of new medicines.

About Solu

We are a Therapeutic Platform Company

Our History

An industrialized platform with transformational potential

Solu Therapeutics was established in May 2023 following the granting of an exclusive license to the CyTAC platform from GSK. Our lead CyTAC program is planned to enter the clinic in early 2025, with a number of exciting CyTAC and TicTAC programs advancing to development candidate status.

Our Mission

To develop a new generation of medicines that transform patient lives

Our Team

Leadership

Phil Vickers, PhD

President & CEO

Michael Boretti, PhD

CBO

Brandon Turunen, PhD

Co-founder, CTO

Kelly Honohan, JD

General Counsel and Company Secretary

John McCabe, MBA

CFO

John Pribis, PhD

Co-founder, Head of Business Strategy

Craig Leach, PhD

VP, Head of Biology

Ron Swearingen, MS

VP, Program Management

Susan Ward, PhD

VP, Clinical Operations

Board Members

Christoph Westphal, MD, PhD

Co-founder, Chairperson
Co-founder & General Partner, Longwood Fund

Phil Vickers, PhD

Director
President & CEO, Solu Therapeutics

Omar Khalil, MSE

Director
Managing Director, Santé Ventures

John Hamer, PhD

Director
Managing Partner, DCVC Bio

Satoshi Konagai, MBA, MSc

Director
Investment Lead, Astellas Venture Managment

Peter Barton Hutt, LL.B., LL.M.

Independent Director
Senior Counsel, Covington & Burling LLP

Scientific Advisory Board

Kipp Weiskopf, MD, PhD

Co-founder and Co-chair of SAB

Kai Wucherpfennig, MD, PhD

Founding SAB member

Stephen Hodi, MD

SAB Member

Kenneth W. Hance, PhD, MPH

SAB Member

Gary Gordon, MD, PhD

Clinical Advisor

Phillip Low, PhD

SAB Member

Investors

News

Careers

Working at Solu

United in excellence and innovation

Solu Therapeutics is a dynamic group of hard-working professionals dedicated to transforming the treatment of diseases by developing groundbreaking medicines. Our team-oriented culture values collaboration, creativity, and fun, fostering an environment where talented individuals can thrive. We're passionate about making a positive difference for people living with many serious and challenging diseases, and we welcome like-minded talents to join our mission.